Shopping Cart
Remove All
Your shopping cart is currently empty
Domagrozumab (PF-06252616) is a humanized monoclonal antibody targeting myostatin, used in studies of muscle wasting diseases.

| Description | Domagrozumab (PF-06252616) is a humanized monoclonal antibody targeting myostatin, used in studies of muscle wasting diseases. |
| In vitro | Domagrozumab is a humanized monoclonal antibody that neutralizes circulating cytokines, thereby preventing receptor activation. Domagrozumab inhibited human myostatin signaling activity with KD = 2.6 pM and IC50 < 1 nM. [1] |
| In vivo | Non-human primates (NHP) treated with Domagrozumab (10 or 30 mg/kg) showed dose-dependent increases in lean body mass and muscle volume, and increased circulating levels of myostatin. [1] |
| Synonyms | PF-06252616, PF06252616 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Siglec-3/CD33 |
| Molecular Weight | 143.96 kDa |
| Cas No. | 1629605-31-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.